Combination Immunotherapy With Ipilimumab and Nivolumab Plus a Dendritic Cell Based p53 Vaccine (Ad.p53-DC) in Patients With Relapsed Small Cell Lung Cancer (SCLC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2018
At a glance
- Drugs INGN 225 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 29 Mar 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 27 Mar 2018 Planned initiation date changed from 1 Apr 2018 to 1 Jun 2018.
- 28 Feb 2018 Planned initiation date changed from 1 Mar 2018 to 1 Apr 2018.